SYSUCC Study on Delaying and Overcoming Drug Resistance in EGFR Gene Mutation-Positive Lung Cancer
ZHOU Huaqiang, ZHAN Jianhua, FANG Wenfeng*, ZHANG Li*
Lung cancer is the most common malignant tumor with the highest incidence and mortality rates in China and worldwide. About 30% of advanced lung cancer patients have EGFR (epidermal growth factor receptor) gene mutations. Currently, both domestic and international lung cancer treatment guidelines recommend using EGFR-TKIs (EGFR-tyrosine kinase inhibitors) as first-line treatment for advanced lung cancer patients with EGFR gene mutations. However, most patients develop resistance to TKI treatment, leading to disease progression. The internal medicine team at the Sun Yat-sen University Cancer Center has conducted innovative research in the field of EGFR mutation-positive lung cancer, ranging from delaying drug resistance to overcoming drug resistance, from combination chemotherapy to novel drugs such as bispecific antibodies and antibody drug conjugates, providing patients with diversified and precise treatment strategies. This article will review the research results of the SYSUCClung cancer team in the field of delaying drug resistance and overcoming drug resistance in EGFR gene mutationpositive lung cancer.
CN
EN